Peter Calabresi - Articles and news items

Biogen Idec logo

Positive year one results from Biogen Idec Phase 3 ADVANCE trial of PLEGRIDY™ presented at AAN Meeting

Industry news, News / 20 March 2013 / Biogen Idec

“These full first-year results provide a more complete picture of PLEGRIDY…”

Novartis logo

Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third large Phase III clinical trial

Industry news, News / 15 December 2011 / Novartis

Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...